Ping Chi, MD, PhD - Publications

Affiliations: 
Memorial Sloan Kettering Cancer Center, Rockville Centre, NY, United States 
 Rockefeller University, New York, NY, United States 
Area:
transcriptional regulation by oncogenic factors
Website:
https://www.mskcc.org/research-areas/labs/ping-chi

25 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, Ganjoo K, Trent J, Gelderblom H, Somaiah N, Hu S, Rosen O, Su Y, Ruiz-Soto R, Gordon M, et al. Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000522. PMID 32804590 DOI: 10.1200/Jco.20.00522  0.328
2020 Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, Schöffski P, Jones RL, Attia S, D'Amato G, Chi P, Reichardt P, Meade J, Shi K, Ruiz-Soto R, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 32511981 DOI: 10.1016/S1470-2045(20)30168-6  0.318
2020 George S, Heinrich MC, Zalcberg JR, Bauer S, Gelderblom H, Schoffski P, Serrano C, Jones RL, Attia S, D'Amato GZ, Chi P, Reichardt P, Lacouture ME, Cha E, Meade JN, et al. Safety profile of ripretinib, including impact of alopecia, and Palmar-Plantar Erythrodysesthesia Syndrome (PPES) on patient-reported outcomes (PROs), in ≥ fourth-line advanced gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11539-11539. DOI: 10.1200/Jco.2020.38.15_Suppl.11539  0.302
2020 Heinrich MC, George S, Zalcberg JR, Bauer S, Gelderblom H, Schoffski P, Serrano C, Jones RL, Attia S, D'Amato GZ, Chi P, Reichardt P, Becker CC, Meade JN, Ruiz-Soto R, et al. Quality of life (QoL) and self-reported function with ripretinib in ≥4th-line therapy for patients with gastrointestinal stromal tumors (GIST): Analyses from INVICTUS. Journal of Clinical Oncology. 38: 11535-11535. DOI: 10.1200/Jco.2020.38.15_Suppl.11535  0.308
2019 Antonescu CR, Dickson BC, Swanson D, Zhang L, Sung YS, Kao YC, Chang WC, Ran L, Pappo A, Bahrami A, Chi P, Fletcher CD. Spindle Cell Tumors With RET Gene Fusions Exhibit a Morphologic Spectrum Akin to Tumors With NTRK Gene Fusions. The American Journal of Surgical Pathology. PMID 31219820 DOI: 10.1097/Pas.0000000000001297  0.311
2019 Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, ... Chi P, et al. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor. The Oncologist. PMID 31213500 DOI: 10.1634/Theoncologist.2019-0418  0.346
2019 Kelly CM, Chi P, Dickson MA, Gounder MM, Keohan ML, Qin L, Adamson T, Condy MM, Biniakewitz M, Phelan H, Singer S, Crago AM, Yoon SS, Ariyan CE, Hwang S, et al. A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma. Journal of Clinical Oncology. 37: 11049-11049. DOI: 10.1200/Jco.2019.37.15_Suppl.11049  0.331
2019 Dickson MA, Koff A, D'Angelo SP, Gounder MM, Keohan ML, Kelly CM, Chi P, Antonescu CR, Landa J, Qin L, Crago AM, Singer S, Tap WD. Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma. Journal of Clinical Oncology. 37: 11004-11004. DOI: 10.1200/Jco.2019.37.15_Suppl.11004  0.34
2019 Janku F, Heinrich M, Chi P, Razak AA, Mehren Mv, Gordon M, Ganjoo K, Trent J, Jones RL, Gelderblom H, Running K, Wang J, Ruiz-Soto R, George S. Abstract CT058: Ripretinib (DCC-2618) pharmacokinetics (PK) in a Phase I study in patients with gastrointestinal stromal tumors (GIST) and other advanced malignancies: A retrospective evaluation of the PK effects of proton pump inhibitors (PPIs) Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct058  0.302
2018 George S, Heinrich M, Chi P, Razak A, von Mehren M, Gordon M, Ganjoo KN, Somaiah N, Trent JC, Rodon Ahnert J, Wolf J, Ruiz-Soto R, Rosen O, Janku F. Initial results of phase I study of DCC-2618, a broad-spectrum KIT and PDGFRa inhibitor, in patients (pts) with gastrointestinal stromal tumor (GIST) by number of prior regimens. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii576-viii577. PMID 32137524 DOI: 10.1093/Annonc/Mdy299.002  0.316
2018 Chang JC, Zhang L, Drilon AE, Chi P, Alaggio R, Borsu L, Benayed R, Travis WD, Ladanyi M, Antonescu CR. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK gene rearrangements. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30550870 DOI: 10.1016/J.Jtho.2018.12.003  0.301
2018 Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, ... Chi P, et al. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Investigational New Drugs. PMID 30101387 DOI: 10.1007/S10637-018-0648-Z  0.317
2018 Xie Y, Cao Z, Wong EW, Guan Y, Ma W, Zhang JQ, Walczak EG, Murphy D, Ran L, Sirota I, Wang S, Shukla S, Gao D, Knott SR, Chang K, ... ... Chi P, et al. COP1-DET1-ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. The Journal of Clinical Investigation. PMID 29360641 DOI: 10.1172/Jci94840  0.312
2018 George S, Heinrich MC, Abdul Razak AR, Chi P, Gordon MS, Ganjoo KN, von Mehren M, Somaiah N, Trent JC, Su Y, Ruiz-Soto R, Rosen O, Janku F. Mutation profile of drug resistant gastrointestinal stromal tumor (GIST) patients (pts) enrolled in the phase 1 study of DCC-2618. Journal of Clinical Oncology. 36: 11511-11511. DOI: 10.1200/Jco.2018.36.15_Suppl.11511  0.308
2018 Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P. Abstract A15: Modeling sporadic gastrointestinal stromal tumor with BRAFV600E mutation Clinical Cancer Research. 24. DOI: 10.1158/1557-3265.Sarcomas17-A15  0.328
2017 Ran L, Chen Y, Sher J, Wong WPE, Murphy D, Zhang JQ, Li D, Deniz K, Sirota I, Cao Z, Wang S, Guan Y, Shukla S, Li KY, Chramiec A, ... ... Chi P, et al. FOXF1 defines the core-regulatory circuitry in gastrointestinal stromal tumor (GIST). Cancer Discovery. PMID 29162563 DOI: 10.1158/2159-8290.Cd-17-0468  0.317
2017 Ran L, Murphy D, Sher J, Cao Z, Wang S, Walczak E, Guan Y, Xie Y, Shukla S, Zhan Y, Antonescu CR, Chen Y, Chi P. ETV1-positive cells give rise to BRAFV600E mutant gastrointestinal stromal tumors. Cancer Research. PMID 28539323 DOI: 10.1158/0008-5472.Can-16-3510  0.332
2015 Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, Landa I, Button J, Lailler N, Sboner A, Gao D, ... ... Chi P, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature. PMID 26444240 DOI: 10.1038/Nature15258  0.334
2015 Ran L, Sirota I, Cao Z, Murphy D, Chen Y, Shukla S, Xie Y, Kaufmann MC, Gao D, Zhu S, Rossi F, Wongvipat J, Taguchi T, Tap WD, Mellinghoff IK, ... ... Chi P, et al. Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth. Cancer Discovery. 5: 304-15. PMID 25572173 DOI: 10.1158/2159-8290.Cd-14-0985  0.345
2015 Chi P, Qin L, Kelly CM, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev B, Crago AM, Yoon SS, Ulaner GA, Martindale M, Condy MM, Phelan H, et al. A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST). Journal of Clinical Oncology. 33: 10507-10507. DOI: 10.1200/Jco.2020.38.15_Suppl.11508  0.34
2010 Chi P, Chen Y, Zhang L, Guo X, Wongvipat J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, Antonescu CR, Allis CD, Sawyers CL. ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature. 467: 849-53. PMID 20927104 DOI: 10.1038/Nature09409  0.324
2003 Chi P, Greengard P, Ryan TA. Synaptic vesicle mobilization is regulated by distinct synapsin I phosphorylation pathways at different frequencies. Neuron. 38: 69-78. PMID 12691665 DOI: 10.1016/S0896-6273(03)00151-X  0.589
2002 Feng J, Chi P, Blanpied TA, Xu Y, Magarinos AM, Ferreira A, Takahashi RH, Kao HT, McEwen BS, Ryan TA, Augustine GJ, Greengard P. Regulation of neurotransmitter release by synapsin III. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 4372-80. PMID 12040043 DOI: 10.1523/Jneurosci.22-11-04372.2002  0.625
2002 Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P. Roscovitine: a novel regulator of P/Q-type calcium channels and transmitter release in central neurons. The Journal of Physiology. 540: 761-70. PMID 11986366 DOI: 10.1113/Jphysiol.2001.013376  0.668
2001 Chi P, Greengard P, Ryan TA. Synapsin dispersion and reclustering during synaptic activity. Nature Neuroscience. 4: 1187-93. PMID 11685225 DOI: 10.1038/Nn756  0.591
Show low-probability matches.